Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 4Stomach Neoplasms 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Diseases 1Neoplasms by Site 1Neoplasms 1Nasopharyngeal Carcinoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Biliary Tract Carcinoma 1

Interventions

Gemcitabine 18pembrolizumab 16Cisplatin 16Nivolumab 15atezolizumab 11durvalumab 9Specimen Handling 9Magnetic Resonance Spectroscopy 9Cystectomy 8Carboplatin 7Ipilimumab 6Fluorouracil 6avelumab 5Mitomycin 5sacituzumab govitecan 4erdafitinib 4enfortumab vedotin 4Surgical Procedures, Operative 4Immunoglobulin G 4Disulfides 4Biopsy 4tremelimumab 3cabozantinib 3Transurethral Resection of Bladder 3Surveys and Questionnaires 3Radiation 3Platinum 3Paclitaxel 3Leucovorin 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urinary Bladder Neoplasms × camrelizumab × Clear all
NCT04706598 2024-07-12

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Fudan University

Phase 1/2 Active not recruiting
25 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡